Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 7/20 | 0.64 |
| ▸ | HDAC6 | Q9UBN7 | 7/20 | 0.64 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.58 |
| ▸ | MDM4 | O15151 | 1/20 | 0.58 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.57 |
| ▸ | CNR1 | P21554 | 1/20 | 0.55 |
| ▸ | CNR2 | P34972 | 1/20 | 0.55 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL42986 | 1.00 | HDAC1 (0.64) | HDAC1HDAC6GRIA1MDM4MDM2 | |
| SCHEMBL27910970 | 0.99 | HDAC1 (0.66) | HDAC1HDAC6GRIA1MDM4MDM2 | |
| SCHEMBL14472130 | 0.99 | HDAC1 (0.66) | HDAC1HDAC6GRIA1MDM4MDM2 | |
| SCHEMBL2337076 | 0.99 | HDAC1 (0.66) | HDAC1HDAC6GRIA1MDM4MDM2 | |
| SCHEMBL18220518 | 0.99 | HDAC1 (0.66) | HDAC1HDAC6GRIA1MDM4MDM2 | |
| SCHEMBL14472192 | 0.99 | HDAC1 (0.66) | HDAC1HDAC6GRIA1MDM4MDM2 | |
| SCHEMBL26114055 | 0.92 | CNR1 (0.67) | HDAC1HDAC6GRIA1CNR1CNR2 | |
| SCHEMBL31370880 | 0.92 | CNR1 (0.67) | HDAC1HDAC6GRIA1CNR1CNR2 | |
| SCHEMBL15132624 | 0.90 | HDAC1 (0.64) | HDAC1HDAC6 | |
| SCHEMBL6650599 | 0.89 | ITGB3 (0.58) | HDAC1HDAC6GRIA1CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240082131-A1 | COMPOSITION FOR IMPROVING SKIN CONDITIONS | NEOPHARM CO., LTD. (KR) | 2024-03-14 | — | — | US | disclosed |
| US-20220142888-A1 | COMPOSITION FOR IMPROVING SKIN CONDITIONS | NEOPHARM CO., LTD. (KR) | 2022-05-12 | — | — | US | disclosed |
| US-20220142888-A1 | COMPOSITION FOR IMPROVING SKIN CONDITIONS | NEOPHARM CO., LTD. (KR) | 2022-05-12 | — | — | US | disclosed |
| US-8809390-B2 | Compound accelerating secretion of human-derived anti-microbial peptide, method for preparing same, and composition having same as active ingredient | NEOPHARM CO., LTD. (KR) | 2014-08-19 | — | — | US | disclosed |
| US-8809390-B2 | Compound accelerating secretion of human-derived anti-microbial peptide, method for preparing same, and composition having same as active ingredient | NEOPHARM CO., LTD. (KR) | 2014-08-19 | — | — | US | disclosed |
| US-20130190397-A1 | NOVEL COMPOUND ACCELERATING SECRETION OF HUMAN-DERIVED ANTI-MICROBIAL PEPTIDE, METHOD FOR PREPARING SAME, AND COMPOSITION HAVING SAME AS ACTIVE INGREDIENT | NEOPHARM CO., LTD. (KR) | 2013-07-25 | — | — | US | disclosed |
| US-20130190397-A1 | NOVEL COMPOUND ACCELERATING SECRETION OF HUMAN-DERIVED ANTI-MICROBIAL PEPTIDE, METHOD FOR PREPARING SAME, AND COMPOSITION HAVING SAME AS ACTIVE INGREDIENT | NEOPHARM CO., LTD. (KR) | 2013-07-25 | — | — | US | disclosed |
| EP-2617707-A1 | NOVEL COMPOUND ACCELERATING SECRETION OF HUMAN-DERIVED ANTI-MICROBIAL PEPTIDE, METHOD FOR PREPARING SAME, AND COMPOSITION HAVING SAME AS ACTIVE INGREDIENT | Neopharm Co., Ltd. (KR) | 2013-07-24 | — | — | EP | disclosed |
| WO-2012026639-A1 | NOVEL COMPOUND ACCELERATING SECRETION OF HUMAN-DERIVED ANTI-MICROBIAL PEPTIDE, METHOD FOR PREPARING SAME, AND COMPOSITION HAVING SAME AS ACTIVE INGREDIENT | (주)네오팜 (KR) | 2012-03-01 | — | — | WO | disclosed |
| CN-102167766-A | Vinyl amino acid (ester) polymer and preparation method thereof | UNIV BEIJING CHEMICAL | 2011-08-31 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130190397-A1 | NOVEL COMPOUND ACCELERATING SECRETION OF HUMAN-DERIVED ANTI-MICROBIAL PEPTIDE, METHOD FOR PREPARING SAME, AND COMPOSITION HAVING SAME AS ACTIVE INGREDIENT | VIP, MRPL37, DBNL | HDAC1 4491/4885HDAC6 3907/4885GRIA1 3808/4885 |
| US-20240082131-A1 | COMPOSITION FOR IMPROVING SKIN CONDITIONS | CUTA, DSG1, IGFBP5 | HDAC1 1559/4885HDAC6 2233/4885GRIA1 4470/4885 |
| US-20220142888-A1 | COMPOSITION FOR IMPROVING SKIN CONDITIONS | CUTA, DSG1, IGFBP5 | HDAC1 1559/4885HDAC6 2233/4885GRIA1 4470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.